MET Variant May be Predictor for Survival, Recurrence in Renal Cell Carcinoma

Share this content:
The MET oncogene rs11762213 may be an independent predictor of survival and recurrence in clear cell renal cell carcinoma.
The MET oncogene rs11762213 may be an independent predictor of survival and recurrence in clear cell renal cell carcinoma.

The MET oncogene rs11762213 may be an independent predictor of adverse cancer-specific survival and time to recurrence in clear cell renal cell carcinoma (ccRCC), according to a recent study published online ahead of print in Cancer.1

Researhcers led by A. Ari Hakimi, MD, of the Memorial Sloan Kettering Cancer Center in New York, NY, looked at 272 patients with ccRCC and known genotype status for rs11762213. Cancer-specific survival was analyzed with the competing risk method while Cox proportional hazard regression was used to analyze for time to recurrence.

They found that the rs11762213 allele was detected in 10.3% of observed patients. Upon adjusting for Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) score, the allele remained a significant predictor for adverse cancer-specific survival and time to recurrence.

RELATED: KIR2DL5B Associated With Poor Response in CML Treated With Sequential Imatinib, Nilotinib

The researchers concluded that the MET variant should be “integrated into clinical practice for prognostic stratification.”

“Genomic analysis suggests that the single-nucleotide polymorphism may affect an enhancer region located in the coding region of MET,” they noted.

Reference

  1. Hakimi AA, Ostrovnaya I, Jacobsen A, et al. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma [published online ahead of print October 27, 2015]. Cancer. doi: 10.1002/cncr.29765.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs